Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
Potential Lawsuits Causing Zantac Manufacturers Heartburn
04:10pm, Monday, 15'th Aug 2022
Concerns over potential liability for a medication purported to cause cancer sliced billions off the value of several manufacturers of the drug in the past week. But were the cuts too deep?
Bert's July Dividend Income Summary | Dividend Investing 2022
04:28am, Monday, 15'th Aug 2022
Our total dividend income decreased from $771.96 received in July 2021. Canadian Imperial takes the crown for the largest dividend payment of the month.
GSK defends Zantac ahead of trials that have wiped off $44 billion from leading drugmakers
07:24pm, Friday, 12'th Aug 2022 MarketWatch
GSK on Friday put out a statement saying there's no link between a withdrawn heartburn medication and cancer, helping to stem a slide in its stock that has wiped out billions of dollars in valuation f
Do I Need to Get A Polio Vaccine? New York Sewer Discovery Triggers Fears About Paralysis-Inducing Virus
07:19pm, Friday, 12'th Aug 2022 Benzinga
New York officials have detected polio in the city's wastewater, suggesting the virus has been circulating in the local area.
What Happened? On Friday, New York State Health Commissioner Dr. Mary Bass
PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation
07:07pm, Friday, 12'th Aug 2022 Zacks Investment Research
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).
PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation
04:33pm, Friday, 12'th Aug 2022
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).
Pharma companies see sales slump amid ongoing Zantac litigation
04:22pm, Friday, 12'th Aug 2022
Yahoo Finance health care reporter Anjalee Khemlani looks at which pharmaceutical stocks are being affected by litigation surrounding alleged carcinogenic materials in Zantac derivatives.
Drugmaker stocks slammed over Zantac lawsuit concerns
02:20pm, Friday, 12'th Aug 2022
Thousands of lawsuits have been filed against companies including Sanofi, GlaxoSmithKline, Haleon and Pfizer accusing them of failing to properly warn users of the recalled heartburn drugs' health ris
GSK and Sanofi Push Back on Zantac Worries. Shares Rebounded.
10:49am, Friday, 12'th Aug 2022
After a UBS analyst's note sparked a two-day plunge in the drug makers, their shares rallied Friday after they said there is no evidence the heartburn drug causes cancer. A J.P. Morgan note also calle
The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals
10:05am, Friday, 12'th Aug 2022 Zacks Investment Research
Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Drugmakers' shares tumble on growing investor fears over Zantac litigation
09:12am, Friday, 12'th Aug 2022
CNBC's Julianna Tatelbaum discusses U.S. litigation focused on heartburn drug Zantac.
GSK defends Zantac ahead of trials that have cratered the stock
04:49am, Friday, 12'th Aug 2022
GSK on Friday put out a statement saying there's no link between a withdrawn heartburn medication and cancer, helping to stem a slide in its stock that has wiped out billions of dollars in valuation f
GSK, Sanofi and Haleon shares stabilise after Zantac litigation slump
04:24am, Friday, 12'th Aug 2022
Shares in GSK, Sanofi
GSK to 'vigorously defend' itself against claims stomach acid drug Zantac causes cancer
04:02am, Friday, 12'th Aug 2022
GSK PLC (LSE:GSK, NYSE:GSK) and Haleon PLC (LSE:HLN, NYSE:HLN) issued separate statements today after their stock was hit by lawsuits claiming GSK's acid indigestion drug Zantac can cause cancer. �
European shares eke out gains at open as healthcare stocks rebound
03:28am, Friday, 12'th Aug 2022
European shares eked out gains on Friday at the open after Sanofi and GSK led a rebound in healthcare stocks, with the main STOXX 600 index set for weekly gains.
